复发/难治性国际预后指数(R/R-IPI):用于复发/难治性弥漫大B细胞淋巴瘤的国际预后计算器
本研究基于SEAL联盟中一线免疫化疗后进展的1234/5112例DLBCL患者,构建了纳入至进展时间和进展时年龄的预后模型,并在LYFO和MER队列中验证。模型在发现集和验证集的c-statistic分别为0.67、0.64和0.68,校准良好,可用于R/R DLBCL的预后判断和治疗决策。
要点
- 至进展时间和进展时年龄是R/R DLBCL进展后OS的强预测因素。
- R/R-IPI模型在发现集和验证集中均显示出良好的区分度和校准度。
- 该工具已集成于智能手机应用,可辅助临床决策和试验设计。
核心结论
- 一线免疫化疗的至进展时间和进展时年龄与DLBCL进展后OS强相关,据此开发的R/R-IPI模型在R/R队列中区分度和校准度良好。
研究设计与样本
- 模型在SEAL联盟中一线免疫化疗后进展的DLBCL患者中构建,并在LYFO和MER队列中进行外部验证。
- SEAL联盟中5112例接受一线免疫化疗的患者有1234例出现疾病进展。
主要发现
- 至进展时间和进展时年龄均与进展后OS显著相关(均p < 0.001)。
- 模型在发现集的c-statistic为0.67,在LYFO和MER验证集的c-statistic分别为0.64和0.68,校准总体良好。
关键数值与推荐
- 模型纳入至进展时间(样条拟合)和进展时年龄(样条拟合)两个变量。
- 模型性能以进展后2年时间依赖的c-statistic和校准指标评估。
临床怎么用
- 可用于R/R DLBCL患者的预后判断,辅助CAR-T治疗等决策及临床试验设计。
- 模型已集成于智能手机床旁应用,便于临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disease progression after frontline therapy for Diffuse large B-cell lymphoma (DLBCL) is a clinically significant event. Patients who experience early progression or have refractory disease have especially poor outcomes. Simple, clinically applicable prognostic tools are needed for selecting patients for consideration for novel therapies and prognostication in the relapsed/refractory (R/R) setting. Model building was performed in patients from the Surrogate endpoints in aggressive lymphoma (SEAL) consortium with disease progression after frontline immunochemotherapy. The primary endpoint was overall survival (OS) measured from date of progression. Validation was performed in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (MER) and Danish National Lymphoma Register (LYFO) cohorts. Model performance was assessed using time-dependent concordance indices (c-statistic) and calibration with metrics evaluated at 2 years from progression. Note, 1234 of 5112 patients treated with frontline immunochemotherapy in the SEAL consortium developed progressive disease. Time to progression on immunochemotherapy and age at progression were strongly associated with post-progression OS (both p < 0.001). A prognostic model was developed incorporating spline fit for both variables. The model had good concordance in the discovery (0.67) and validation sets (LYFO c = 0.64, MER c = 0.68) with generally good calibration. Time to progression on frontline therapy is strongly associated with post-progression OS in DLBCL. We developed and validated a simple to apply clinical prognostic tool in the R/R setting. The useful prediction of expected outcomes in R/R DLBCL and can inform treatment decisions such as considerations for CAR-T therapy as well as trial designs. The model is available in smartphone-based point of care applications.
引用
- Maurer MJ, Jakobsen LH, Mwangi R, et al. Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. Am J Hematol. 2021. PMID: 33661547. doi:10.1002/ajh.26149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。